The idea behind Biopharma BD&L Summit is to drive partnerships through mergers and acquisitions (“M&A”), especially given the slowed research and development (“R&D”) as a result of the pandemic and industry changes such as those resulting from newly introduced regulations. Based on these facts, combined with the possibility of making mistakes at different stages of the M&A process, the Biopharma BD&L summit is designed to provide an unrivaled deep-dive into partnership strategies, licensing priorities and ways to avoid making mistakes at different stages of the M&A process.
The two-day event will be held virtually on April 22 and 23. It will feature presentations and panel discussions from over 20 speakers who hold senior positions in the MedTech industry, a testament to their experience. Besides the presentations and panel discussions, the summit will provide networking opportunities. Notably, it is a comprehensive event designed for many professionals, including those who deal with licensing, legal/IP, due diligence, search and evaluation, compliance, scientific assessment, transactions, portfolio/life cycle management and many more. Biopharma BD&L aims to drive collaborative partnerships to enhance the drug development ecosystem through smart and savvy deal-making.
To register, visit https://dgevents.com/event/biopharma-bdl-summit/